Latest News for SILO
Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment SARASOTA, Fla, April 29, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today commends a wave of coordinated U.
Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment
Silo Pharma, Inc. (NASDAQ: SILO - Get Free Report) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totaling 522,541 shares, a growth of 58.6% from the March 31st total of 329,449 shares. Based on an average trading volume of 18,681,437 shares,
Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1 SARASOTA, FL, April 22, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced a strategic business expansion into AI technology as a second line of business…
Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1 SARASOTA, FL, April 22, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced a strategic business expansion into AI technology as a second line of business…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SILO.
U.S. House Trading
No House trades found for SILO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.